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Aim: The aim of this study was to determine the effect of morphine on bladder cancer cell proliferation and apoptosis in vitro. 
Materials and Methods: MTT assay was used to measure percentage growth of RT-112 human bladder cancer cells after 72 hours 
of morphine/morphine + naloxone treatment. Expression of µ-opioid receptors was assessed by Western blot and finally, apoptotic 
assay with CellEvent Caspase-3/7 Green Detection Reagent was carried out using confocal microscopy. Results: The MTT assays 
showed that morphine increased RT-112 cell growth. Naloxone inhibited this growth enhancing effect. Western blot analysis regard-
ing µ-opioid receptor expression in RT-112 cells remains inconclusive. Morphine was also found to decrease the rate of apoptosis 
of RT-112 cells, an effect which naloxone inhibited. Conclusions: This study provides evidence that morphine, at clinically relevant 
doses, causes RT-112 bladder cancer cell proliferation, possibly opioid receptor mediated and at least some of this effect might 
be due to decreased apoptosis. Clinically, this suggests that in patients with bladder cancer, managing pain with morphine might 
have detrimental consequences on patient outcomes and alternative pain relief should be considered if possible.
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Bladder cancer is the ninth most common cancer 
worldwide, encompassing several types of cancer which 
arise from the urothelium. According to GLOBOCAN 
estimates, around 430,000 new bladder cancer cases 
and 165,000 bladder cancer deaths occurred globally 
in 2012 [1]. Morphine plays a role in the management 
of bladder cancer, specifically, in peri-operative anal-
gesia during tumour resections and radical cystectomy 
for more advanced disease. However, in recent years, 
evidence has come to light suggesting that opioids 
might be undesirable in cancer management.
A number of retrospective clinical studies have 
demonstrated a lower incidence of cancer recurrence 
after regional anaesthesia and reduced use of opioids 
after surgery [2–4]. Laboratory-based studies have 
reported large amounts of conflicting evidence regard-
ing morphine influence on cell proliferation, apoptosis, 
invasion/migration and angiogenesis.
The anti-proliferative effects of morphine on can-
cer cells have been demonstrated in various cell 
lines including MCF-7 breast cancer cells (due 
to the activation of opioid receptors) [5], T47D human 
breast cancer cells (despite lacking opioid recep-
tors) [6], PC9 lung cancer cells (due to the inhibi-
tion of NF-kB and TNF-α) [7] and finally in LNCaP, 
DU145 and PC3 human prostate cancer cells [8]. 
On the contrary, pro-proliferative effects of morphine 
have been noted in EL-4 leukaemia cells in mice 
(although this may have been secondary to immuno-
suppression) [9], K562 human leukaemia cells [10] 
and HT-29 colon cancer cells (through the increased 
secretion of the metastasising protein urokinase-type 
plasminogen activator) [11].
Similar uncertainty has been shown when looking 
at morphine effect on cancer cell apoptosis. Anti-apop-
totic effects have been demonstrated in SH-SY5Y neuro-
blastoma cells through a PI3K-signalling cascade [12]. 
However, using this same cell line, a different study 
found morphine to induce apoptosis through activation 
of the mitochondrial death pathway [13]. Pro-apoptotic 
effects have also been demonstrated in small cell lung 
cancer cells (due to a reduction in protein kinase C ac-
tivity) [14] and Jurkat leukaemia cells [15].
This study aims to determine the in vitro effects 
of morphine on bladder cancer cell proliferation and 
apoptosis. It is hypothesised that morphine, at clini-
cally relevant concentrations, will enhance bladder 
cancer cell proliferation, possibly due to an inhibitory 
effect on apoptosis through an opioid receptor-me-
diated mechanism.
MATERIALS AND METHODS
Reagents. Unless otherwise stated, all reagents 
were purchased from Sigma-AldrichTM, UK: Morphine 
sulphate salt pentahydrate; Naloxone methiodide; me-
thylthiazolyldiphenyl-tetrazolium bromide (MTT); RPMI 
medium; foetal calf serum; 1% L-Glutamine-Penicillin-
Streptomycin solution; 0.4% trypan blue; phosphate 
buffered saline; Dimethyl sulfoxide; Sodium dodecyl 
sulphate. µ-opioid primary antibody (ab10275) and 
secondary antibody (ab205718) were from Abcam, 
UK; CellEvent Caspase-3/7 Green Detection Reagent 
was from Thermofisher ScientificTM, UK.
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Cell culture. RT-112 human urinary bladder 
transitional carcinoma cells were maintained in RPMI 
medium supplemented with 10% foetal calf serum 
and 1% L-Glutamine-Penicillin-Streptomycin solu-
tion. The cells were incubated at 37 °C in a humidified 
atmosphere with 5% CO2 and passaged when they 
reached 90% confluence.
MTT assay. RT-112 cells (1 • 105) were seeded 
into the 60 inner wells of 96-well microplates contain-
ing 100 µl of culture medium. Phosphate buffered 
saline was added to the outer 36 wells. Plates were 
incubated at 37 °C in 5% CO2 for 24 hours. Doubling 
dilutions of treatment/blocker was then added to the 
wells (n = 6) except for the eleventh column which was 
kept as a control. Plates were incubated for a further 
72 hours. 50 µl of MTT solution was added to each well. 
Precipitated formazan crystals were dissolved by adding 
100 µl dimethyl sulfoxide. The plates were inserted into 
the spectrophotometer and read at 570 nm and 630 nm. 
Each MTT assay was repeated 4 times.
Immunoblotting. RT-112 cells were lysed in break-
ing buffer (50 mM sodium phosphate, 1 mM PMSF, 
1 mM EDTA, 5% glycerol). 10 µg aliquots of protein 
sample were mixed with 6 × SDS loading buffer, incu-
bated for 10 minutes at 75 °C and loaded on a 4–20% 
gradient polyacrylamide gel along with the molecular 
weight marker. The proteins were then transferred 
onto a nitrocellulose membrane at 30 mA for 2 hours. 
Following SDS-polyacrylamide gel electrophoresis 
and electroblotting, membranes were blocked using 
a 5% milk solution for 2 hours. Following this, they were 
incubated with the µ-opioid primary antibody (1:1000) 
and subsequently the secondary antibody for 2 hours 
each (1:1000). Antibody-labelled protein bands were 
visualised by enhanced chemiluminescent detection. 
Coomassie staining was used to exhibit the protein 
profile of the RT-112 cells.
Apoptosis assay. RT-112 cells (1 • 105) were 
seeded into a µ-Slide 8-Well Glass Bottom dish. Cells 
were incubated at 37 °C in 5% CO2 for 24 hours and 
then treated with morphine/naloxone. The dishes were 
incubated for a further 72 hours. After removing the 
media from the cells, CellEvent Caspase-3/7 Green 
Detection Reagent (Thermofisher ScientificTM, UK) was 
added to the cells. Cells were imaged using confocal 
microscopy.
Statistical analysis. MTT assay — results from 
the plate reader were analysed using Graphpad Prism 
(Graphpad Software, San Diego, CA). p values were 
calculated by comparing the control average with 
an experimental average using Student’s paired t-tests. 
The 62.5 µM experimental value was deemed the most 
clinically relevant and therefore was appropriate for sta-
tistical analysis to compare against the control [16, 17].
Apoptotic assay — the number of apoptotic cells 
showing bright green nuclei were calculated as a per-
centage of the total number of cells and analysed using 
Graphpad Prism.
RESULTS
Growth response of RT-112 cells to exo-
genous morphine. Morphine doubling dilutions 
(250 µM à 0.977 µM) were performed across a 96-
well plate. As shown in Fig. 1, the percentage growth 
of the treated cells was greater than that of the control 
cells. This effect diminished as morphine concentra-
tions decreased. At the 62.5 µM (clinically relevant) 
concentration, there was ~7% increase in cell growth 
(p = 0.0079), whereas at the lowest concentrations 
of morphine, there was negligible effect.
Growth response of RT-112 cells to morphine 
after pre-treatment with clinically relevant nalo-
xone dose. A 50 µM blanket dose of naloxone was 
applied across a 96-well plate, 15 minutes prior 
to morphine doubling dilutions (250 µM à 0.977 µM). 
Initially, at the higher doses of morphine, percentage 
growth was higher than that of the control (Fig. 2). 
At the 62.5 µM morphine dose, the increase in growth 
was ~2% which was not significantly different from the 
control (p = 0.7445) and this was most likely due to the 
competitive binding of naloxone at the opioid recep-
tors. As morphine concentrations dropped below the 
50 µM naloxone dose, percentage growth decreased 
to below that of the control.
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Fig. 1. Growth response of RT-112 cells to exogenous morphine. Bar chart showing the percentage difference between growth of the 
treated cells and control cells Statistics is calculated for 62.5 µM compared to control using Student’s paired t-test. **p < 0.05
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RT-112 cell expression of the µ-opioid recep-
tor. The next step in this study was to determine if the 
µ-opioid receptor was expressed by RT-112 cells. In dot 
blot experiments with µ-opioid receptor antibody only 
a weak signal was obtained. While in Western blot analy-
sis a weak signal corresponded to a molecular weight 
of 25-30 kDa while the predicted molecular weight of the 
µ-opioid receptor is 45 kDa (data not shown).
Effect of morphine on RT-112 cell apoptosis. 
Confocal imaging was used to determine whether 
morphine, with and without naloxone, had any effect 
on RT-112 cell apoptosis. Fig. 3, a displays the most 
representative image of each well in the 8-well glass 
dish and the treatment that each well received. Note that 
many images were taken across each well, all of which 
were analysed during cell counting. Fig. 3, b quanti-
fies the findings from these images. The percentage 
of apoptotic cells was ~13% in the morphine (50 µM) 
group ([p = 0.1345), ~28% in the morphine (50 µM) + 
naloxone (100 µM) group (p = 0.6594) and ~24% in the 
control group. Despite not achieving statistical signifi-
cance, these results remain interesting and informative 
and perhaps shed some light on how morphine exerts 
its growth-inducing effects.
DISCUSSION
This study adds further evidence to the debate 
that morphine may be undesirable in the management 
of pain, in patients with bladder cancer (transitional 
cell carcinoma). Fig. 1 shows that clinically relevant 
doses of morphine cause RT-112 cell proliferation, 
corresponding to 5–10% growth increase. Other 
studies have found comparable results, for example, 
with human glioma T98G cells [18] and human colon 
cancer HCT116 cells (believed to be caused by modu-
lation of cell proliferation and/or apoptosis) [19]. 
In these studies the concentrations of morphine used 
were below 1 µM, however, evidence suggests that 
in peri-operative patients receiving morphine, plasma 
concentrations can reach higher than 70 µM [16]. 
This is why 62.5 µM was deemed a clinically relevant 
concentration in these experiments.
When morphine and naloxone were co-adminis-
tered, they demonstrated a competitive relationship. 
Fig. 2 shows that when morphine concentration exceed-
ed naloxone concentration, the result was RT-112 cell 
proliferation. However, when naloxone concentration 
exceeded morphine concentration, cell growth was re-
duced. Percentage growth ranged from +10% to –15% 
across the plate. This suggests that the growth-enhanc-
ing effects of morphine are opioid receptor-mediated.
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Fig. 3. The effect of morphine on RT-112 cell apoptosis. 
a — Confocal images showing the number of apoptotic cells 
in each well (fluorescent green). M — morphine-treated well; 
M + N — morphine- and naloxone-treated well; C — control 
well. b — Bar chart showing the percentage of apoptotic cells 
in the different treatment groups
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Fig. 2. Growth response of RT-112 cells to morphine after pre-treatment with clinically relevant naloxone dose 50 µM. Bar chart 
showing the percentage difference between growth of the treated cells and growth of the control cells Statistics is calculated for 
62.5 µM compared to control using Student’s paired t-test. ns — non-significant (p > 0.05) 
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Involvement of the µ-opioid receptor in regulat-
ing cancer progression has been reported in several 
laboratory studies [20–22]. To determine whether 
RT-112 cells express µ-opioid receptors, several im-
munoblotting experiments were performed. Neverthe-
less, Western blot analysis regarding µ-opioid receptor 
expression in RT-112 cells in our study remained incon-
clusive. Finally, in our experiments morphine reduces 
the rate of apoptosis in RT-112 cells, which may partly 
explain how morphine causes RT-112 cell proliferation. 
Naloxone inhibited morphine anti-apoptotic effect. 
Lin et al. reported similar findings where morphine 
inhibited doxorubicin-induced neuroblastoma cell 
apoptosis by the inhibition of reactive oxygen species 
generation, mitochondrial cytochrome c release and 
NF-kB transcriptional activation [23]. Morphine has 
also been shown to protect lymphocytic cells from 
apoptotic lysis, mediated by opioid receptors [24].
In our study, morphine, at clinically relevant 
doses, caused RT-112 bladder cancer cell prolifera-
tion. The results support an opioid receptor medi-
ated effect and at least some of this might be due 
to decreased apoptosis. This has not been reported 
previously for a bladder cancer cell line but concurs 
with other studies carried out on different cancer cell 
lines. Clinically, the use of morphine to manage pain 
in patients with bladder cancer may need to be care-
fully considered.
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